HopeStage
Back to all studies
WithdrawnNCT04016792

Classroom Study of SPN-812 in Children With ADHD

Researchers are comparing 200 mg SPN-812 and placebo, tracking side effects to assess safety in children with ADHD.

Medication studyAges 6–11
The study in practice

Understand this study

What is this study about?

Researchers are comparing 200 mg SPN-812 and placebo, tracking side effects to assess safety in children with ADHD.

Who could participate?

This study is for people with ADHD. Listed age limits: 6 years to 11 years. Other eligibility criteria apply.

Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateEstimated: August 2019
Recruitment status
Withdrawn
Enrollment listed in the registry
0
Sponsor
Supernus Pharmaceuticals, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Not clearly listed
Age range
From 6 Years to 11 Years
Official registry ID
NCT04016792
Official title
Show the full official title

An Analog Classroom Study: Efficacy and Safety of SPN-812 in Children With Attention-Deficit/Hyperactivity Disorder

Recruitment & locations

Withdrawn

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing 200 mg SPN-812 and placebo, tracking side effects to assess safety in children with ADHD.

Who is behind this study?

The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.

Does this study involve medication?

Yes. The study involves medication, including Placebo and 200 mg SPN-812.

Who can participate?

This study is for people with ADHD. Listed age limits: 6 years to 11 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as withdrawn.

Want to explore more studies?

Explore studies